BW
PCVX icon

Basepoint Wealth’s Vaxcyte PCVX Stock Holding History

Basepoint Wealth’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18K Buy
+38
New +$2.06K ﹤0.01% 514

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Basepoint Wealth's PCVX Position: Q2 2026 in Review

Basepoint Wealth opened a new position in Vaxcyte (PCVX) in Q2 2026: 38 shares worth $2.18K. The stake represents ﹤0.01% of the portfolio and ranks #514 among its holdings.

331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Basepoint Wealth held 38 shares of Vaxcyte worth $2.18K as of Q2 2026.
  • Vaxcyte was a new Basepoint Wealth position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Basepoint Wealth's portfolio in Q2 2026, its #514 holding.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Basepoint Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.